8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  February 26, 2008

CALIPER LIFE SCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	0-28229	33-0675808
(State or other jurisdiction of incorporation)	(Commission  File Number)	(IRS Employer Identification No.)
68 Elm Street, Hopkinton, Massachusetts		01748
(Address of Principal Executive Offices)		(Zip Code)
(508) 435-9500
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Forum 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Ex-99.1 Press Release dated February 26, 2008

2

Item 2.02. Results of Operations and Financial Condition.

On February 26, 2008, Caliper Life Sciences, Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2007. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Caliper Life Sciences, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless Caliper Life Sciences specifically states that it is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit Number	Description of Document
99.1	Press release of Caliper Life Sciences, Inc. announcing financial results for the fourth quarter and full year ended December 31, 2007.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CALIPER LIFE SCIENCES, INC.
February 26, 2008	By:	/s/ Thomas T. Higgins
		Thomas T. Higgins Executive Vice President and Chief Financial Officer

4

EX-99.1

EXHIBIT 99.1

For Immediate Release

Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results

- Fourth Quarter Revenue Growth 16% -

- IVIS Imaging Systems Cross 500^th Placement Milestone -

HOPKINTON, Mass., February 26, 2008 — Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery and life sciences research, today reported its fourth quarter and full year financial results for 2007. Fourth quarter revenues were $40.3 million, an increase of 16% from $34.7 million in the same period in 2006. Net loss for the quarter was $5.7 million ($0.12 per share), compared to a net loss of $8.9 million ($0.19 per share) in the same quarter of 2006. Full year 2007 revenues were $140.7 million, up 30% from $107.9 million in 2006. Net loss for the full year was $24.1 million ($0.51 per share), compared to a net loss of $28.9 million ($0.75 per share) in 2006.  Caliper attributed its fourth quarter revenue growth to strong performance by its IVIS imaging and its microfluidics products, and attributed its $3.2 million fourth quarter reduction in net loss primarily to product and service gross margin improvements.

Highlights in the quarter include:

·Product revenue increased 19% in comparison with the fourth quarter of 2006. IVIS molecular imaging systems achieved a new record with 44% revenue growth and 51 unit placements increasing the installed unit base to 537 systems. Significantly, the company saw an increase in use of IVIS systems in new therapeutic areas beyond oncology, including central nervous system (CNS) disorders, infectious and metabolic disease, and inflammation. Microfluidics instrument revenue recorded 26% revenue growth led by demand for the new EZ Reader products which are used primarily in kinase screening. Automation instrument revenue for the quarter was level with the fourth quarter of 2006.

·Service revenue grew 18% in comparison with the fourth quarter of 2006. Caliper Discovery and Alliances Services (“CDAS”) posted strong 29% growth reflecting the new EPA ToxCast contract awarded in the second quarter of 2007, plus expanded in vivo phenotyping business with pharmaceutical companies. Instrument maintenance and other services posted high single digit growth.

·Combined product and service gross margins improved to 42% versus the fourth quarter of 2006. The gain of over 270 basis points in gross margins compared to the fourth quarter of 2006 reflected increased volumes, as well as savings from raw materials sourcing initiatives.

·Operating expenses (R&D plus SG&A) increased by $1.2 million from the fourth quarter of 2006. This was primarily due to costs associated with ongoing litigation.

·Positive operating cashflow was generated in the quarter, and Caliper ended the period with $19.0 million in cash and marketable securities.

“In the fourth quarter of 2007, we achieved strong revenue performance in all of our key growth drivers: the IVIS Spectrum imaging instrument, the microfluidics-based EZ Reader instrument

and the associated ProfilerPro product line of reagents, the Zephyr desktop liquid handler, and CDAS in vitro and in vivo services.  This evidence of market support reinforces our belief that our products and services are well positioned for double digit revenue growth in 2008,” said Kevin Hrusovsky, president and CEO of Caliper. “Our bottom line reflects a continuing trend of improvement, particularly in product gross margins which gained over 500 basis points in 2007 compared with 2006. There is room to do more. We have 2008 initiatives in place to better manage manufacturing materials and inventory, as well as improve the efficiency of our operating expense spending.”

2008 GAAP Guidance

Caliper reported that its revenue outlook for the first quarter of 2008 is $26.5 to $29.5 million and its revenue outlook for the full year 2008 is $142 to $148 million. Caliper’s revenue outlook encompasses combined product and service revenue for the first quarter of 2008 of $24 to $27 million and for the full year 2008 of $132 to $138 million, representing 5.4% and 12% product and service revenue growth at the midpoint of the respective ranges.

Adjusted Results

Caliper supplements its GAAP financial reporting with certain non-GAAP financial measures. A reconciliation of Caliper’s GAAP to non-GAAP Statements of Operations is provided at the end of this release under “Adjusted Consolidated Statements of Operations.” Adjusted results of operations exclude stock-based compensation charges and acquisition-related revenue adjustments and expenses, such as amortization of intangibles and restructuring charges and credits. Caliper believes that providing this additional information enhances investors’ understanding of the financial performance of Caliper’s operations and increases the comparability of its current financial statements to prior periods.

In the fourth quarter of 2007, Caliper reported adjusted revenue of $40.3 million, an increase of 13% over the fourth quarter of 2006, and an adjusted net loss of $2.0 million ($0.04 per share), in comparison with an adjusted net loss of $2.4 million ($0.05 per share) in the fourth quarter of 2006. For the full year 2007, Caliper reported adjusted revenue of $141.7 million, an increase of 29% over 2006, and an adjusted net loss of $7.9 million or ($0.17) per share in comparison with an adjusted net loss of $10.0 million or ($0.26) per share in 2006.

Caliper will discuss its fourth quarter and full year results in a conference call to be held today, February 26 at 9:00 a.m. EST. To participate in the call, please dial 888-713-4215 five to ten minutes prior to the call and use the participant passcode 54563865. International callers can access the call by dialing 617-213-4867 and entering the same passcode.  You may also pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PKKMX3XKF.

A live webcast of the call can be accessed at www.fulldisclosure.com or on the Caliper website at www.caliperLS.com in the Events section of the Investor Relations page. A webcast replay of the call will remain available until Caliper’s earnings call for the first quarter of 2008.

Telephone replays of the conference call will be available approximately two hours after the completion of the call on February 26 until March 4, 2008. To access a telephone playback of the proceedings, dial 888-286-8010 and use the participant passcode 19800700. International callers can access the playback by dialing 617-801-6888 and using the same participant passcode.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease.  Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding future events, including statements regarding Caliper’s expected financial results for the first quarter ending March 31, 2008 and for fiscal year 2008, Caliper’s beliefs regarding the future growth rate performance of its IVIS imaging products, the strong revenue growth potential of Caliper’s microfluidics products, and the effect of the EPA ToxCast contract on future revenues and margins, are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including the risks that unexpected difficulties may be encountered in gaining wider commercial adoption of Caliper’s new products, that the EPA may not expand the screening of compounds under the ToxCast contract as much or as rapidly as expected by Caliper, and that Caliper’s expectations regarding demand for its products and services may not materialize if capital spending by Caliper’s customers declines, if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its drug discovery and imaging systems and other products. Further information on risks faced by Caliper are detailed under the caption “Risks Related To Our Business” in Caliper’s Annual Report on Form 10-K for the year ended December 31, 2006. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

NOTE:  Caliper, Xenogen, IVIS and LabChip are registered trademarks, and Spectrum, Zephyr, EZ Reader and ProfilerPro are trademarks, of Caliper Life Sciences, Inc. or its subsidiaries.

Contacts:	Media:
Thomas Higgins	Stacey Holifield or Melissa Bruno
Chief Financial Officer	Schwartz Communications
508.497.2809	781.684.0770

CALIPER LIFE SCIENCES, INC.

SELECTED FINANCIAL INFORMATION

(unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months Ended December 31,						Year Ended December 31,
	2007			2006			2007			2006
Revenue:
Product revenue	$	28,175		$	23,739		$	82,961		$	69,248
Service revenue	9,513			8,088			37,557			24,454
License fees and contract revenue	2,568			2,893			20,189			14,169
Total revenue	40,256			34,720			140,707			107,871
Costs and expenses:
Cost of product revenue	15,961			14,029			49,760			45,459
Cost of service revenue	5,756			5,184			22,357			14,917
Cost of license revenue	277			146			2,515			219
Research and development	5,702			6,542			24,791			24,591
Selling, general and administrative	15,642			13,630			54,954			43,570
Amortization of intangible assets	2,514			4,314			10,106			8,842
Restructuring charges, net	22			161			52			258
Total costs and expenses	45,874			44,006			164,535			137,856
Operating loss	(5,618		)	(9,286		)	(23,828		)	(29,985		)
Interest income (expense), net	(226		)	8			(547		)	478
Other income (expense), net	213			90			579			469
Benefit (provision) for income taxes	(103		)	301			(284		)	104
Net loss	$	(5,734	)	$	(8,887	)	$	(24,080	)	$	(28,934	)
Net loss per share, basic and diluted	$	(0.12	)	$	(0.19	)	$	(0.51	)	$	(0.75	)
Shares used in computing net loss per common share, basic and diluted	47,561			46,652			47,301			38,743

CALIPER LIFE SCIENCES, INC.

SELECTED FINANCIAL INFORMATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

	December 31,
	2007		2006
	(unaudited)		(Note 1)
Assets
Current assets:
Cash and cash equivalents	$	15,709	$	11,634
Marketable securities	3,246		13,303
Accounts receivable, net	30,248		30,822
Inventories	19,572		18,758
Other current assets	2,353		2,273
Total current assets	71,128		76,790
Property and equipment, net	11,477		13,182
Intangible assets, net	42,862		52,806
Goodwill	80,836		80,776
Other assets	1,626		1,499
Total assets	$	207,929	$	225,053
Liabilities and stockholders’ equity
Current liabilities	$	45,391	$	49,938
Loans payable and other long-term obligations	21,352		17,706
Stockholders’ equity	141,186		157,409
Total liabilities and stockholders’ equity	$	207,929	$	225,053

Note (1): Derived from audited financial statements for the year ended December 31, 2006.

CALIPER LIFE SCIENCES, INC.

ADJUSTED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months Ended
	December 31, 2007													December 31, 2006
		Reported			Stock-based Comp			Other Adjustments			Adjusted (1)			Reported			Stock-based Comp			Other Adjustments			Adjusted (1)
Revenues:
Product revenue	(4)	$	28,175		$	—		$	—		$	28,175		$	23,739		$	—		$	—		$	23,739
Service revenue		9,513			—			—			9,513			8,088			—			—			8,088
License fees and contract revenue	(4)	2,568			—			20			2,588			2,893			—			1,017			3,910
Total revenues		40,256			—			20			40,276			34,720			—			1,017			35,737
Cost and Expenses:
Cost of product revenue	(2), (4)	15,961			(93		)	—			15,868			14,029			(133		)	—			13,896
Cost of service revenue	(2)	5,756			(22		)	—			5,734			5,184			(40		)	—			5,144
Cost of license revenue	(4)	277			—			—			277			146			—			95			241
Research and development	(2)	5,702			(212		)	—			5,490			6,542			(252		)	—			6,290
Selling, general and administrative	(2)	15,642			(865		)	—			14,777			13,630			(1,068		)	—			12,562
Amortization of intangible assets	(3)	2,514			—			(2,514		)	—			4,314			—			(4,314		)	—
Restructuring charges	(3)	22			—			(22		)	—			161			—			(161		)	—
Total costs and expenses		45,874			(1,192		)	(2,536		)	42,146			44,006			(1,493		)	(4,380		)	38,133
Operating loss		(5,618		)	1,192			2,556			(1,870		)	(9,286		)	1,493			5,397			(2,396		)
Interest income (expense), net		(226		)	—			—			(226		)	8			—			—			8
Other income, net		213			—			—			213			90			—			—			90
Benefit (provision) for income taxes	(6)	(103		)	—			—			(103		)	301			—			(386		)	(85		)
Net income (loss)		$	(5,734	)	$	1,192		$	2,556		$	(1,986	)	$	(8,887	)	$	1,493		$	5,011		$	(2,383	)
Net income (loss) per share — basic and diluted		$	(0.12	)							$	(0.04	)	$	(0.19	)							$	(0.05	)
Shares used in computing net loss per share — basic and diluted		47,561									47,561			46,652									46,652

See accompanying Notes to Adjusted Consolidated Statements of Operations

CALIPER LIFE SCIENCES, INC.

ADJUSTED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

		Year Ended
		December 31, 2007												December 31, 2006
		Reported			Stock-based Comp			Other Adjustments			Adjusted (1)			Reported			Stock-based Comp			Other Adjustments			Adjusted (1)
Revenues:
Product revenue	(4)	$	82,961		$	—		$	—		$	82,961		$	69,248		$	—		$	273		$	69,521
Service revenue		37,557			—			—			37,557			24,454			—			—			24,454
License fees and contract revenue	(4)	20,189			—			1,037			21,226			14,169			—			1,603			15,772
Total revenues		140,707			—			1,037			141,744			107,871			—			1,876			109,747
Cost and Expenses:
Cost of product revenue	(2), (4)	49,760			(422		)	—			49,338			45,459			(506		)	9			44,962
Cost of service revenue	(2)	22,357			(121		)	—			22,236			14,917			(151		)	—			14,766
Cost of license revenue	(4)	2,515			—			138			2,653			219			—			149			368
Research and development	(2), (5)	24,791			(836		)	—			23,955			24,591			(975		)	(2,898		)	20,718
Selling, general and administrative	(2)	54,954			(3,783		)	—			51,171			43,570			(3,938		)	—			39,632
Amortization of intangible assets	(3)	10,106			—			(10,106		)	—			8,842			—			(8,842		)	—
Restructuring charges	(3)	52			—			(52		)	—			258			—			(258		)	—
Total costs and expenses		164,535			(5,162		)	(10,020		)	149,353			137,856			(5,570		)	(11,840		)	120,446
Operating loss		(23,828		)	5,162			11,057			(7,609		)	(29,985		)	5,570			13,716			(10,699		)
Interest income, net		(547		)	—			—			(547		)	478			—			—			478
Other income, net		579			—			—			579			469			—			—			469
Provision for income taxes	(6)	(284		)	—			—			(284		)	104			—			(386		)	(282		)
Net income (loss)		$	(24,080	)	$	5,162		$	11,057		$	(7,861	)	$	(28,934	)	$	5,570		$	13,330		$	(10,034	)
Net income (loss) per share — basic and diluted		$	(0.51	)							$	(0.17	)	$	(0.75	)							$	(0.26	)
Shares used in computing net loss per share — basic and diluted		47,301									47,301			38,743									38,743

Notes to Adjusted Consolidated Statements of Operations

(1)To supplement the financial results presented on a GAAP basis, the Company uses adjusted measures of gross profit margins, costs and expenses, net loss and net loss per share which are non-GAAP financial measures. Caliper’s management uses these adjusted financial measures to gain an understanding of its comparative operating performance, and also in financial and operating decision-making because management believes they better reflect the underlying economics of Caliper’s ongoing business. Management believes that comparisons of adjusted financial measures may be more meaningful because operating results presented under GAAP may include, from time to time, items that management believes are not necessarily relevant to understand Caliper’s business. Caliper’s management believes that these adjusted financial measures provide useful information to investors and others in understanding and evaluating Caliper’s current operating performance and future prospects. The adjusted financial measures have limitations, however, because they do not include all items of income and expense that impact Caliper’s operations. The adjusted measures exclude:

a)Expense associated with the amortization of acquisition-related intangible assets, impairment of acquired intangible assets and in-process research and development. This exclusion allows comparisons of operating results that are consistent over time for both the Company’s newly acquired and long-held business activities and with both acquisitive and non-acquisitive peers.

b)Deferred revenue adjustments recorded in purchase accounting that reduce revenues that would otherwise be recognized on a continuing GAAP basis.

c)Restructuring expense related reductions in force and costs to discontinue activities including idle capacity costs. The costs largely relate to restructuring activities associated with business combinations and are not indicative of the Company’s normal operating costs.

d)The Company adopted Statement of Financial Accounting Standards (SFAS) No. 123R on January 1, 2006, which requires non-cash stock compensation expense to be recorded when stock options and other stock-related awards vest. The Company is using the Modified-Prospective Transition method in its adoption of SFAS No. 123R and, as such, is not required to restate prior year results for the impact of stock-related awards expensing.  The Company believes that available valuation methodologies and assumptions may

result in estimates that are misleading in the comparison of its financial results to previous periods or to its peers, and do not provide meaningful insight into the Company’s ongoing operations.

(2)Adjustment represents stock-based compensation expense.

(3)Adjustment represents intangible asset amortization and impairment charges and restructuring activities related to business combinations.

(4)Adjustment represents revenues and related costs that were recorded at fair value in accordance with the provisions of SFAS No. 141 and EITF No. 01-03. As a result, these amounts were excluded from the reported results on a GAAP basis, however, due to the fact they relate to purchase accounting, they have been added back on an Adjusted basis.

(5)Adjustment represents in-process research and development charge related to the Xenogen acquisition.

(6)Adjustment represents tax effect of intangible asset impairment charges.